id: NEW:nonalcoholic_fatty_liver_disease_nafld_to_cardiovascular_disease_mortality
name: Nonalcoholic Fatty Liver Disease (NAFLD) â†’ Cardiovascular Disease Mortality
from_node:
  node_id: NEW:nonalcoholic_fatty_liver_disease_nafld
  node_name: Nonalcoholic Fatty Liver Disease (NAFLD)
to_node:
  node_id: cardiovascular_disease_mortality
  node_name: Cardiovascular Disease Mortality
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: NAFLD leads to hepatic insulin resistance and systemic metabolic dysfunction,
  promoting atherogenic dyslipidemia and chronic low-grade inflammation'
- 'Step 2: Liver-derived inflammatory mediators (cytokines, hepatokines) and procoagulant
  factors enter systemic circulation, promoting endothelial dysfunction and accelerated
  atherosclerosis'
- 'Step 3: High prevalence of comorbid metabolic syndrome (41.73%), cardiovascular
  disease (16.83%), hypertension, dyslipidemia, and diabetes in NAFLD patients compounds
  cardiovascular risk'
- 'Step 4: Progressive cardiovascular damage leads to increased incidence of cardiovascular
  events (24.77 per 1,000 person-years) and ultimately CVD-related mortality (4.53
  per 1,000 person-years)'
evidence:
  quality_rating: A
  n_studies: 79
  primary_citation: 'M. Le et al. 2024. Global incidence of adverse clinical events
    in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinical
    and Molecular Hepatology.'
  supporting_citations: []
description: NAFLD is associated with increased cardiovascular disease mortality through
  multiple interconnected biological pathways. The meta-analysis of 79 studies (1,377,466
  persons) found CVD-related mortality incidence of 4.53 per 1,000 person-years in
  NAFLD patients. The mechanism involves hepatic metabolic dysfunction driving systemic
  inflammation, atherogenic lipid profiles, and insulin resistance. High baseline
  prevalence of metabolic comorbidities in NAFLD populations (metabolic syndrome 41.73%,
  CVD 16.83%) indicates shared pathophysiology and cumulative cardiovascular risk.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 4.53
    type: incidence_rate_per_1000_person_years
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: 1377466
moderators:
- name: geographic_region
  direction: strengthens
  strength: moderate
  description: North America and Europe show higher CVD mortality rates compared to
    other regions
- name: time_period
  direction: weakens
  strength: moderate
  description: Time-period analyses showed decreasing rates of cardiovascular mortality
    over recent periods (P<0.05), possibly due to improved CVD management
- name: NASH_status
  direction: strengthens
  strength: weak
  description: Biopsy-proven NASH associated with higher incidence of liver-related
    complications; relationship to CVD mortality not significantly different
